Short Report

You have full text access to this OnlineOpen article

Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population

  1. Guy D. Launoy1,†,*,
  2. Hughes J. Bertrand2,
  3. Celia Berchi1,
  4. Vincent Y. Talbourdet2,
  5. Anne Valérie N. Guizard2,
  6. Véronique M. Bouvier1,
  7. Emile R. Caces3

Article first published online: 7 FEB 2005

DOI: 10.1002/ijc.20921

Issue

International Journal of Cancer

International Journal of Cancer

Volume 115, Issue 3, pages 493–496, 20 June 2005

Additional Information

How to Cite

Launoy, G. D., Bertrand, H. J., Berchi, C., Talbourdet, V. Y., Guizard, A. V. N., Bouvier, V. M. and Caces, E. R. (2005), Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int. J. Cancer, 115: 493–496. doi: 10.1002/ijc.20921

Author Information

  1. 1

    Cancers and Populations, INSERM Faculté de Médecine, Caen, France

  2. 2

    Cancer Registry of La Manche Department, Tours, France

  3. 3

    Institut Régional pour la Santé, Tours, France

  1. †

    Fax: +33-0231530852

*Cancers and Populations, INSERM, Faculté de Médecine, CHU 14000, Caen, France

Publication History

  1. Issue published online: 7 APR 2005
  2. Article first published online: 7 FEB 2005
  3. Manuscript Accepted: 28 OCT 2004
  4. Manuscript Received: 9 JUL 2004

Funded by

  • Caisse Nationale d'Assurance Maladie
  • Direction générale de la Santé
  • Ligue contre le Cancer (La Manche)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (76K)

References

  • 1
    Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, Exbrayat C, Tretare B, Carli PM, Guizard AV, Troussard X, Bercelli P, et al. Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publ 2003; 51: 3–30.
  • 2
    Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for faecal occult blood. N Engl J Med 1993; 343: 1603–7.
  • 3
    Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomized controlled trial of fecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472–7.
  • 4
    Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with fecal-occult-blood test. Lancet 1996; 348: 1467–71.
  • 5
    Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, Dassonville F, Bonithon-Kopp C. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004; 126: 1674–80.
  • 6
    Gyrd-Hansen D, Sogaard J, Kronborg O. Analysis of screening data: colorectal cancer. Int J Epidemiol 1997; 27: 1172–81.
  • 7
    Launoy G, Smith T, Duffy S, Bouvier V. Colorectal cancer mass-screening: estimation of faecal occult blood sensitivity, taking into account cancer mean sojourn time. Int J Cancer 1997; 73: 220–4.
    Direct Link:
  • 8
    Jouve JL, Remontet L, Dancourt V, Lejeune C, Benamiche AM, Faivre J, Estève J. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening. Br J Cancer 2001; 84: 1477–81.
  • 9
    Young G, St John J, Winawer S, Rozen P. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies. Am J Gastroenterol 2002; 97: 2499–507.
  • 10
    Zappa M, Castiglione G, Paci E, Grazzini G, Rubeca T, Turco P, Crocetti E, Ciatto S. Measuring interval cancers in population-based screening using different assays of faecal occult blood testing: the district of Florence experience. Int J Cancer 2001; 92: 151–4.
    Direct Link:
  • 11
    Wong WM, Lam SK, Cheung KL, Tong TS, Rozen P, Young GP, Ho J, Law WL, Tung HM, Choi HK, Lee YM, Lai KC, et al. Evaluation of an automated immunochemical fecal occult blood for colorectal neoplasia in a Chinese population. Cancer 2003; 15: 2420–4.
    Direct Link:
  • 12
    Bouvier V, Launoy G, Herbert C, Lefevre H, Maurel J, Gignoux M. Colorectal cancer after a negative Haemoccult II test and program sensitivity after a first round of screening. The experience of the department of Calvados (France). Br J Cancer 1999; 81: 305–9.
  • 13
    Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal cancer screening. N Engl J Med 1996; 334: 155–9.
  • 14
    Rozen P, Knaani J, Samuel Z. Comparative screening with a sensitive guaiac and specific immunochemical occult blood test in an endoscopic study. Cancer 2000; 89: 46–52.
    Direct Link:
  • 15
    Berchi C, Bouvier V, Reaud JM, Launoy G. Cost–effectiveness analysis of two strategies for mass screening of colorectal cancer in France. Health Econ 2003; 13: 227–38.
    Direct Link:
  • 16
    Castiglione G, Grazzini G, Miccinesi G, Rubeca T, Sani C, Turco P, Zappa M. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen 2002; 9: 99–103.
  • 17
    Mandel J, Church T, Bond J, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603–7.
View Full Article (HTML) Get PDF (76K)